PR Newswire Asia's news > Biotechnology

 < Previous page   |   Detail   |   Print    Next page > 
     
Alebund Pharmaceuticals Announces 2026 Interim Results
2026-08-26T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
China's BCI Race Accelerates: Gestala Raises US$84 Million in Six Months
2026-08-26T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
2026-08-26T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
HaemaLogiX Announces Major Milestone with First Patient Successfully Dosed with KMCARâ„¢ T-Cell
2026-08-26T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Metabolon Completes Landmark Global Health Pilot Advancing Women's and Infant Health
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
WuXi Biologics Reports Strong Profitable Growth in H1 2026
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Fosun Pharma Announces 2026 Interim Results
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Innovent Announces 2026 Interim Results and Business Updates
2026-08-25T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Haisco enters into Exclusive License Agreement with new US venture founded by Population Health Partners and ARCH Venture Partners
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Cambrex High Point Completes FDA, PMDA and TGA Pre-Approval Inspections, Advancing Commercial Manufacturing Capabilities
2026-08-25T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.